Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Yan-Jiao Yu"'
Autor:
Zi-Lu Huang, Aalaa Sanad Abdallah, Guang-Xin Shen, Milagros Suarez, Ping Feng, Yan-Jiao Yu, Ying Wang, Shuo-Han Zheng, Yu-Jun Hu, Xiang Xiao, Ya Liu, Song-Ran Liu, Zhong-Ping Chen, Xiao-Nan Li, Yun-Fei Xia
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 19, p 14707 (2023)
Glioblastoma multiforme (GBM) is a highly aggressive malignancy and represents the most common brain tumor in adults. To better understand its biology for new and effective therapies, we examined the role of GDP-mannose pyrophosphorylase B (GMPPB), a
Externí odkaz:
https://doaj.org/article/e6ffa191ffce4fefb4ae71a8283cb162
Publikováno v:
Palaeoentomology. 5
Here we analyze four ancient amber artifacts of the Han Dynasty (202 BCE–220 CE) by using Fourier transform infrared spectroscopy to reveal their origins. The FTIR results showed the presence of the Baltic shoulder band between 1210–1150 cm-1 and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa48354cf264cccc783f9338528771c3
https://doi.org/10.11646/palaeoentomology.5.4.8
https://doi.org/10.11646/palaeoentomology.5.4.8
Autor:
Zhongping Chen, Hai-Ping Cai, Zhi-Hui Yu, Yi-Ying Zhao, Guokai Feng, Xiang-Rong Ni, Fu-Rong Chen, Jing Wang, Yan-Jiao Yu
Publikováno v:
Journal of Neuro-Oncology. 148:245-258
Optical molecular imaging technology that indiscriminately detects intracranial glioblastoma (GBM) can help neurosurgeons effectively remove tumor masses. Transferrin receptor 1 (TfR 1) is a diagnostic and therapeutic target in GBM. A TfR 1-targeted
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94ad405c8f2e6f6e9af5dd41671ec275
https://doi.org/10.1007/s11060-020-03527-3
https://doi.org/10.1007/s11060-020-03527-3
Autor:
Qi-Tao Huang, Yan-Jiao Yu, Shaoyan Xi, Jia-Bin Lu, Zhongping Chen, Hai-Ping Cai, Yu Zhang, Fu-Rong Chen, Fang Wang
Publikováno v:
Oncogene
Research over the past decade has suggested important roles for pseudogenes in glioma. This study aimed to show that pseudogene PRELI domain-containing 1 pseudogene 6 (PRELID1P6) promotes glioma progression. Aberrant expression of genes was screened
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bfc9d8e7191fcb7a358f4e163171cd4
https://pubmed.ncbi.nlm.nih.gov/34108621
https://pubmed.ncbi.nlm.nih.gov/34108621
Autor:
Cong Li, Yan-Jiao Yu, Zhongping Chen, Shaoyan Xi, Jing Wang, Hai-Ping Cai, Yuanjun Hu, Fu-Rong Chen, Xiang-Rong Ni
Publikováno v:
Cell Death & Disease
Long noncoding RNAs (lncRNAs), once considered to be nonfunctional relics of evolution, are emerging as essential genes in tumor progression. However, the function and underlying mechanisms of lncRNAs in glioma remain unclear. This study aimed to inv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3ce720c82e3c65c31d36a2f6382cf93
https://doi.org/10.1038/s41419-020-03247-6
https://doi.org/10.1038/s41419-020-03247-6
Autor:
Guokai Feng, Zhi-Hui Yu, Hai-Ping Cai, Fu-Rong Chen, Yan-Jiao Yu, Zhongping Chen, Yi-Ying Zhao, Jing Wang, Xiang-Rong Ni
Publikováno v:
Neuro Oncol
OBJECTIVE A new imaging technology that indiscriminately detects intracranial glioblastoma (GBM) can help neurosurgeons remove tumor mass completely. Transferrin receptors (TfR 1) have been widely investigated as a diagnostic and therapeutic target i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b2ac5c11dbf419aad4242c04798163e
https://europepmc.org/articles/PMC7651001/
https://europepmc.org/articles/PMC7651001/
Autor:
Jing Wang, Wei-Chi Wu, Zhongping Chen, Chengcheng Guo, Fu-Rong Chen, Zhi-Hui Yu, Xiang-Rong Ni, Jun-Xiao Ma, Hai-Ping Cai, Yan-Jiao Yu
Publikováno v:
Cancer chemotherapy and pharmacology. 86(6)
Glioma, especially glioblastoma (GBM), is the most aggressive malignant brain tumor and its standard therapy is often ineffective because of temozolomide (TMZ) resistance. Reversal of the TMZ resistance might improve the prognosis of glioma patients.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44dbe63e6a5bda7c04f27b0e7a501931
https://pubmed.ncbi.nlm.nih.gov/33074386
https://pubmed.ncbi.nlm.nih.gov/33074386
Autor:
Shao yan Xi, Ji Zhang, Zhongping Chen, Xiang rong Ni, Cheng Cheng Guo, Zi wen Cen, Chao Ke, Yin Sheng Chen, Hai ping Cai, Jing Wang, Fu-Rong Chen, Jian Wang, Zhi hui Yu, Yan jiao Yu
Publikováno v:
Cell Death & Disease
Cell Death and Disease, Vol 10, Iss 12, Pp 1-14 (2019)
Cell Death and Disease, Vol 10, Iss 12, Pp 1-14 (2019)
Vasculogenic mimicry (VM), the formation of vessel-like structures by highly invasive tumor cells, has been considered one of several mechanisms responsible for the failure of anti-angiogenesis therapy in glioma patients. Therefore, inhibiting VM for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dafcbb66b0649d245bd0104165f617c8
http://europepmc.org/articles/PMC6872754
http://europepmc.org/articles/PMC6872754
Publikováno v:
Neuro Oncol
INTRODUCTION Glioma is the primary malignancy with the highest incidence in central nervous system. Studies have shown that glioma stem cell (GSC) is the important origin for recurrence and closely associated with tumor microenvironment. Glioma-assoc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0d90b80c9959ba0fac044c9ab9f30f1
https://doi.org/10.1093/neuonc/noaa215.836
https://doi.org/10.1093/neuonc/noaa215.836
Autor:
Yan-Jiao Yu, Chengcheng Guo, Yue Qu, Xiang-Rong Ni, Qunying Yang, Jing Wang, Hai-Ping Cai, Zhongping Chen, Fu-Rong Chen
Publikováno v:
Neuro Oncol
OBJECTIVE Temozolomide (TMZ), is the first line chemotherapeutic drug for glioma. Previous studies have suggested that interferon (IFN) and levetiracetam (LEV) could respectively reverse the resistance of TMZ by down-regulating MGMT expression. This
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0966ea1a1b05baa5ee2af903bf4bc4e
https://doi.org/10.1093/neuonc/noz175.295
https://doi.org/10.1093/neuonc/noz175.295